0QW0.LSE Argen-X
- Market cap
- EUR 13.4B
- P/E
- -
- P/B
- -
- ROE
- 39.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0QW0.LSE undervalued?
Graham numberThe Graham number of Argen-X cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Argen-X fundamental analysis
No fundamental analysis for Argen-X yet.
Argen-X stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis …
Full company profileArgen-X financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Argen-X annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.5M | 43.7M | 24.6M | 78.5M | 41.2M | 497M | 411M | 1.23B | 2.25B | 4.24B | 11.4B |
| Gross Profit | 15.5M | 43.7M | 24.6M | 78.5M | 41.2M | 497M | 381M | 1.11B | 1.01B | 2.42B | 6.64B |
| Operating Income | -22.5M | -27.5M | -93.6M | -199M | -478M | -349M | -720M | -425M | -21.7M | 1.05B | 3.55B |
| EBITDA | -22.2M | -32.4M | -93.1M | -173M | -601M | -393M | -623M | -192M | 3.39M | 1.08B | 3.62B |
| Net Income | -22.5M | -33.7M | -76.2M | -181M | -608M | -408M | -710M | -295M | 804M | 1.29B | 3.36B |
| EPS | -1.19 | -1.37 | -2.12 | -4.69 | -13 | -7.74 | -13 | -5.16 | 12 | 20 | 52 |
| Balance Sheet | |||||||||||
| Total Assets | 111M | 445M | 662M | 1.61B | 2.28B | 2.85B | 3.13B | 4.54B | 5.99B | 8.68B | 10.0B |
| Total Liabilities | 44.6M | 31.2M | 45.8M | 430M | 605M | 316M | 321M | 445M | 680M | 1.36B | 1.62B |
| Shareholders' Equity | 66.7M | 414M | 616M | 1.18B | 1.67B | 2.53B | 2.81B | 4.10B | 5.31B | 7.32B | 8.43B |
| Cash & Short-term Investments | 102M | 432M | 646M | 1.50B | 2.00B | 2.34B | 2.19B | 3.18B | 3.26B | 4.44B | 5.19B |
| Total Debt | - | - | - | 7.32M | 9.66M | 11.5M | 12.4M | 20.0M | 37.7M | 47.2M | 47.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.1M | -43.8M | -61.6M | 152M | -398M | -607M | -863M | -420M | -82.7M | 685M | - |
| Capital Expenditure | 906K | 421K | 782K | 46.7M | 5.14M | 121M | 104M | 43.8M | 1.74M | 6.16M | 6.05M |
| Free Cash Flow | 10.2M | -44.3M | -62.4M | 105M | -404M | -728M | -967M | -464M | -81.6M | 679M | - |
| Ratios | |||||||||||
| ROE | -33.7% | -8.1% | -12.4% | -15.4% | -36.3% | -16.1% | -25.2% | -7.2% | 15.2% | 17.6% | 39.8% |
| ROA | -20.2% | -7.6% | -11.5% | -11.3% | -26.7% | -14.3% | -22.6% | -6.5% | 13.4% | 14.9% | 33.4% |
| Net Profit Margin | -145.3% | -77.1% | -310.2% | -231.0% | -1,475.3% | -82.1% | -172.8% | -24.1% | 35.8% | 30.5% | 29.4% |
| Debt to Equity | - | - | - | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Argen-X dividends
Argen-X has not paid dividends in the last 9 fiscal years.
Who owns Argen-X
- Insiders 0.01%
- Institutions 49.39%
- Public & others 50.61%
- Shares outstanding 32.5M
- Free float 62.4M
Argen-X company profile
- Company name
- Argen-X
- Ticker
- 0QW0.LSE
- ISIN
- NL0010832176
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 1,863
- Fiscal year end
- December
- Address
- Laarderhoogtweg 25, Amsterdam, Netherlands, 1101 EB
- Phone
- 31 10 703 8441
- Website
- argenx.com
About Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Argen-X management
10- Mr. Timothy Van Hauwermeiren EMBA, M.Sc.Co-Founder & Non-Independent Non-Executive Chairman of the Board · born 1972
- Ms. Karen MasseyCEO & Executive Director · born 1979
- Mr. Karl GubitzChief Financial Officer · born 1970
- Dr. Peter UlrichtsChief Scientific Officer · born 1980
- Ms. Malini MoorthyGeneral Counsel & Corporate Secretary · born 1970
- Mr. Arjen Lemmen M.Sc.VP of Corporate Development & Strategy · born 1985
- Ms. Andria WilkGlobal Head of Quality · born 1973
- Dr. Luc TruyenChief Medical Officer · born 1965
- Prof. Hans de Haard Ir, Ph.D.Co-Founder & Member of Board Advisors · born 1960
- Mr. Filip BorgionsChief Technology Innovation Officer